ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
HSP90β as a potential prognostic biomarker in urothelial carcinoma: insights from NF-κB, IL-8, and heat-shock protein expression.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrothelial carcinoma (UC) is a common malignancy with high recurrence rates and limited prognostic markers. Inflammation and stress-response pathways are implicated in tumor progression, with NF-κB, interleukin-8 (IL-8), and heat shock proteins (HSP90α/β) playing key roles in survival signaling and treatment resistance. We evaluated the expression of these proteins in UC and assessed their associations with clinicopathological features.
methodsFormalin-fixed, paraffin-embedded samples from 102 UC patients (168 tumor sections) and 23 controls were analyzed by immunohistochemistry for NF-κB, IL-8, HSP90α, and HSP90β. Expression was semi-quantitatively scored using the immunoreactive score (IRS) and correlated with clinicopathological features using non-parametric tests.
resultsNuclear NF-κB expression was significantly higher in UC compared with normal urothelium and correlated with tumor stage and nodal involvement. IL-8 was expressed in 53.6% of tumors and 48.8% of adjacent infiltrates but showed no association with grade, stage, or lymph node status; a weak positive correlation with inflammatory infiltrate was observed. Both HSP90 isoforms were upregulated in UC relative to controls, but only HSP90β correlated with grade, stage, and lymph node status. No significant correlations were found between NF-κB, IL-8, and HSP90 expression.
conclusionsHSP90β expression shows potential as a prognostic biomarker and therapeutic target in UC. Although NF-κB and IL-8 did not demonstrate consistent prognostic value, their patterns highlight the role of inflammatory signaling in tumor biology. These findings warrant validation in larger, more diverse cohorts and support exploration of HSP90-targeted strategies in UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.